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Abstract 
Anemia is common in patients undergoing percutaneous coronary intervention (PCI), and 
current guidelines fail to offer recommendations for its management. This review aims to 
examine the relation between baseline anemia and mortality, major adverse cardiovascular 
events (MACE), and major bleeding in patients undergoing PCI. We searched MEDLINE 
and EMBASE for studies that evaluated mortality and adverse outcomes in anemic and 
nonanemic patients who underwent PCI. Data were collected on study design, participant 
characteristics, definition of anemia, follow-up, and adverse outcomes. Random effects meta-
analysis of risk ratios was performed using inverse variance method. A total of 44 studies 
were included in the review with 230,795 participants. The prevalence of baseline anemia 
was 26,514 of 170,914 (16%). There was an elevated risk of mortality and MACE with 
anemia compared with no anemia-pooled risk ratio (RR) 2.39 (2.02 to 2.83), p <0.001 and 
RR 1.51 (1.34 to 1.71), p <0.001, respectively. The risk of myocardial infarction and bleeding 
with anemia compared with no anemia was elevated, pooled RR 1.33 (1.07 to 1.65), p = 0.01 
and RR 1.97 (1.03 to 3.77), p <0.001, respectively. The risk of mortality per unit incremental 
decrease in hemoglobin (g/dl) was RR 1.19 (1.09 to 1.30), p <0.001 and the risk of mortality, 
MACE, and reinfarction per 1 unit incremental decrease in hematocrit (%) was RR 1.07 (1.05 
to 1.10), p = 0.04, RR 1.09 (1.08 to 1.10) and RR 1.06 (1.03 to 1.10), respectively. The 
prevalence of anemia in contemporary cohorts of patients undergoing PCI is significant and 
is associated with significant increases in postprocedural mortality, MACE, reinfarction, and 
bleeding. The optimal strategy for the management of anemia in such patients remains 
uncertain.
Introduction 
 Anaemia is common amongst patients undergoing percutaneous coronary 
interventions (PCI) with prevalent rates reported between 10-23% in randomised controlled 
trials (1-3)and rates greater than 30% reported in observational registries (4,5). Current 
clinical guidelines fail to offer recommendations for its concurrent management in patients 
undergoing PCI. Patients with anaemia who undergo PCI are frequently older (5-7), with 
multiple co-morbidities including higher rates of renal failure (1,8-11), diabetes (1,8), 
previous history of myocardial infarction (12,13) and more extensive and complex coronary 
disease (12-14). These clinical and procedural characteristics are well known to be associated 
with poorer outcomes post PCI. Previous studies have reported that the presence of baseline 
anaemia is independently associated with mortality (5,8,9,15) and major adverse cardiac 
events (MACE)(5,16) and major bleeding complications(17) and several PCI risk scores have 
used anaemia as important predictors for both mortality (18) and bleeding outcomes (19,20). 
In contrast, other studies suggest that whilst these relationships exists for unadjusted data, 
anaemia is no longer associated with increased mortality following adjustment for potential 
confounders such as age, comorbidity burden and procedural demographics, (16,21-23), 
MACE (11,23)or ischemic complications (2). Other studies have also suggested an 
independent association with mortality only in males but not females (1). Anaemia may occur 
following major bleeding events or in the presence of chronic renal disease, or relate to the 
presence of a diverse range of chronic diseases(24). Whilst both major bleeding (25,26) and 
chronic renal disease are known to independently predict adverse outcomes following 
PCI(27-29), several analyses that have focussed on the prognostic impact of anaemia have 
not adjusted for either renal function (6,30) or major bleeding events that may further 
confound relationships reported.  
 To the best of our knowledge, there has not been a systematic review or meta-analysis 
of the prevalence and prognostic impact of anaemia in the setting of PCI. We have therefore 
undertaken a meta-analysis to systematically study the impact of anaemia in patients who 
have undergone PCI on mortality, MACE, major bleeding and re-infarction and attempt to 
dissect out whether the associations reported between anaemia and adverse clinical outcomes 
are independent of clinical and procedural characteristics that are more prevalent in patients 
with anaemia and portend to worse outcomes. Finally, we study whether the reported 
relationships reported between anaemia and clinical outcomes are similar irrespective of 
whether the PCI is undertaken in the elective or ACS setting.  
 
Methods 
Eligibility criteria 
We selected studies of participants who underwent PCI and reported any of the 
following adverse outcomes: mortality, MACE by any definition or combination of (adverse 
cardiovascular events and mortality), re-infarction and bleeding among patients who were 
anemic and non-anemic (no restriction on cutoffs of hemoglobin).  We also included studies 
that evaluated the risk of adverse outcomes for incremental increase or decrease in 
hemoglobin.  Studies that did not clearly report any of the adverse outcomes by anemia status 
or incremental changes in hemoglobin were excluded.   
Search strategy  
A search of MEDLINE and EMBASE was performed on OVID SP.  The exact search 
strategy is shown in Supplementary Data 1.  There was no restriction on the search based on 
language and both abstracts and unpublished literature were included.  The bibliography of 
included studies and relevant reviews were evaluated for additional studies.  Authors were 
contacted in situations where there was uncertainty regarding the data in the studies. 
Study selection and data extraction 
Three reviewers (C.S.K., A.P. and A.A.) independently screened all titles and 
abstracts for studies potentially meeting the inclusion criteria.  The full reports of these 
studies were retrieved, and data from each study were extracted independently by two 
reviewers (C.S.K. and D. T.) Data extracted included study design, participant characteristics, 
participant inclusion criteria, definition of anemia or incremental hemoglobin change, adverse 
outcomes, follow up and results.   
 
Quality assessment 
Additional data was collected on quality of studies that included ascertainment of 
anemia, ascertainment of outcomes, loss to follow up and use of adjustments for 
confounding.  Publication bias was assessed using funnel plots for an analysis with >10 
studies and no evidence of substantial heterogeneity(31). 
Data analysis 
We used RevMan (version 5.3, Nordic Cochrane Centre, Copenhagen, Demark) to 
perform random effects meta-analysis using inverse variance methods for pooling risk ratios.  
We assumed similarity between odds ratio and other relative measures such as relative risk, 
rate ratios and hazard rations because cardiovascular events were rare events(32). We chose 
to pool adjusted results were available and crude results when adjusted results were not 
available.  For datasets with the multiple time points were chose to pool the longest time-
point in the primary analysis.  The I2 statistic was used to assess statistical heterogeneity. 
We performed the primary analysis considering unadjusted and adjusted results for 
anemic and non-anemic patients for the outcomes mortality, MACE, re-infarction and 
bleeding.  Secondary analysis was performed considering the incremental decrease in 
hemoglobin and the risk of adverse outcomes.  For the main anemia and risk of mortality 
analysis, we performed sensitivity analysis considering only studies that adjusted for baseline 
hemoglobin, renal impairment and severity of anemia and mortality.  Further analysis was 
performed considering the effect of elective or ACS patients on outcomes. 
 
Results 
Study selection 
The process of study selection is shown in Figure 1.  A total of 44 studies were 
included in this meta-analysis with a total of with 230,795 participants.  The number of 
participants ranged from 100 to 73,067 and the overall prevalence of anaemia was 
26,514/170,914 (16%) and for individual studies the prevalence ranged from 3% to 41%. 
 
Description of studies included 
 The study design, date of study, country of origin and indications for PCI are shown 
in Table 1.  There were 4 post hoc analyses of randomised controlled trials, 14 prospective 
cohort studies, 14 retrospective cohort studies and 12 cohort studies of unclear design.  There 
were 15 studies of patients with STEMI, 1 study of just STEMI patients and 28 studies of 
patients undergoing PCI.   
 
Quality assessment 
 Table 2 shows the risk of bias table for the included studies.  All of the studies aside 
for one specified that blood measurements were taken prior to PCI and the single study with 
unclear timing of blood sampling was presumed to be prior to PCI.  A variety of methods 
were used to ascertain adverse outcomes after PCI.  These included evaluating hospital 
records, interviewing patients, families, personal physicians, use of national death records 
and use of independent events adjudication committees.  A total of 15 studies did not specify 
how outcomes were ascertained.  The loss to follow up was reported in 18 studies and was 
unclear in the remaining studies.  All studies reported at least one adjusted analysis except for 
5 studies. 
 
Risk of adverse outcomes with anaemia compared to no anaemia 
 The study definitions of anaemia, follow up and results are shown in Table 3.  The 
risk of mortality and major adverse cardiovascular events (MACE) with anaemia compared to 
no anaemia was RR 2.39 (2.02-2.83) (32 studies, 134,042 participants) (Figure 2) and RR 
1.51 (1.34-1.71) (20 studies, 47,552 participants) (Figure 3), respectively.  The risk of re-
infarction and bleeding with anaemia compared to no anaemia was RR 1.33 (1.07-1.65) (13 
studies, 36,316 participants) (Figure 4) and RR 1.97 (1.03-3.77) (11 studies, 34,388 
participants) (Figure 5), respectively.   
 
Incremental decrease in haemoglobin or haematocrit and adverse outcomes 
 The analysis for incremental decrease in haemoglobin and haematocrit is shown in 
Figure 6.  The risk of mortality for incremental decrease in haemoglobin (g/dl) was RR 1.19 
(1.09-1.30) (7 studies, 82,208 participants) and the risk of mortality, MACE and re-infarction 
for incremental decrease in haematocrit (%) was RR 1.07 (1.05-1.10) (3 studies, 14,519 
participants), RR 1.09 (1.08-1.10) (1 study, 6,025 participants) and RR 1.06 (1.03-1.10) (1 
study, 6,025 participants), respectively. 
 
Subgroup analysis of anaemia compared to no anaemia 
 Sensitivity analysis was performed considering the subgroup of studies that had used 
adjustments for baseline haemoglobin and renal impairment and studies which evaluated 
severity of anaemia (Figure 7).  The pooled results of 3 studies that adjusted for baseline 
haemoglobin showed a significant increase in mortality (RR 1.81 (1.62-2.01)) and a 
significantly higher mortality were observed for studies that adjusted for renal impairment of 
renal function (RR 2.05 (1.69-2.49)).  Kitai et al was the only study of mortality outcomes 
which considered severity of anaemia and they reported that mild anaemia (>10 g/dL) was 
associated with RR 1.86 (1.42-2.43) while moderate to severe anaemia (<10 g/dL) was 
associated with greater mortality (RR 3.35 (2.52-4.46)). 
Further analyses considering elective cases only, ACS cases only and any PCI cases 
separately are shown in Supplementary Figures 1-4.  After adjustments, there were significant 
increases in mortality for patients with anaemia in both the ACS and elective setting.  
However, there was only a significant increase in mortality with incremental decrease in 
haemoglobin in elective cases but not ACS.  Similarly, anaemia was independently associated 
with worse MACE and bleeding outcomes in both the elective and ACS PCI setting. 
 
Discussion 
 To the best of our knowledge, the present analysis is the first to systematically review 
the prevalence of anaemia in contemporary cohorts undergoing PCI to study its prognostic 
impact. Our meta-analysis of 44 studies including 230,795 patients has shown that the mean 
prevalence of anaemia in contemporary PCI is 16% and is independently associated with a 2-
fold increased risk of mortality, MACE events and major bleeding with elevation in risk with 
incremental decreases in haemoglobin levels. This increased risk appears to be independent 
of the common causes of anaemia such as chronic renal disease of bleeding events sustained 
peri-procedurally, and the increased risk of adverse events associated with anaemia is of 
similar magnitude in both the elective and ACS setting. 
 Previous studies have reported conflicting data regarding the association between 
anaemia and clinical outcomes in patients undergoing PCI, with studies reporting both an 
independent association with increased mortality, MACE and major bleeding complications 
(3,5,8-10,15-17) or no increase in risk following adjustment for differences in age, 
comorbidity burden and procedural demographics (9,21,22), or only associated with poorer 
outcomes in patients with severe anaemia but not mild or moderate anaemia (11). Other 
studies have suggested that post-procedural anaemia is independently associated with MACE 
(23).  
 There are a number of biological and clinical reasons why chronic anaemia may lead 
to worse clinical outcomes in patients undergoing PCI. Our analysis suggests that anaemia is 
independently associated with a two-fold increased risk of major bleeding complications, 
which themselves are independently associated with increased risks of peri-procedural and 
longer-term mortality (26). Other studies suggest that anaemia may also independently 
increase the risk of definite and definite or probable stent thrombosis by 250% (9), which 
might contribute to the increased mortality risk in this patient cohort. In support of this, an 
analysis of 73,067 patients from the National Cardiovascular Data Registry Acute Coronary 
Treatment and Intervention Outcomes Network Registry - Get With the Guidelines 
(ACTION-GWTG) (33) demonstrated that patients with anaemia were less likely to be 
prescribed dual antiplatelet therapy peri-procedurally, which might contribute to increased 
risks of future stent thrombosis. Furthermore, patients with haemoglobin <10 g/dl had an 
overall transfusion rate that was 6.5-fold higher compared with patients with haemoglobin 
>12 g/dl (64.2% vs 9.9%, p <0.0001). A previous meta-analysis has suggested that the receipt 
of a blood transfusion in the PCI setting is independently associated with a 3-fold increase in 
mortality and MACE, and this risk persists even in the absence of major bleeding events (34). 
Similarly, other studies have also reported that patients with anaemia do not receive optimal 
antiplatelet therapy post PCI (3) although Pilgrim et al. report that the presence of anaemia 
did not influence the choice of peri-procedural antithrombotic or antiplatelet regime at the 
time of hospital discharge post PCI (9). Finally anaemia may merely be a marker of a greater 
co-morbid in frailer patients, and the statistical models may have been affected by incomplete 
adjustments for confounders such as co-morbid burden or frailty. Our previous work has 
shown that co-morbidity burden is significant in patients undergoing PCI and is 
independently associated with adverse shorter and longer-term clinical outcomes (35). 
 Whilst our meta-analysis highlights the independent association between the presence 
of anaemia and adverse clinical outcomes in the PCI setting, there are no current 
recommended guidelines for the treatment of anaemia, with no clarity as to whether there is a 
threshold level of anaemia at which treatment should be considered. Previous reports derived 
from the National Cardiovascular Data Registry dataset of transfusion practice nationally in 
the PCI setting have reported significant variations in the prevalence of transfusion events in 
hospitals across the United States, with significant differences in haemoglobin threshold that 
prompts transfusion(36). Furthermore, randomised trials have yielded conflicting data 
regarding optimal treatment of anaemia in ACS and PCI settings, for example, in the CRIT 
(conservative versus liberal red cell transfusion in acute myocardial infarction) randomized 
pilot trial, 45 patients with myocardial infarction and anaemia were randomized to either a 
liberal transfusion arm or a conservative arm, with worse outcomes reported in patients 
assigned to the liberal transfusion arm (composite endpoint of in-hospital mortality, re-
infarction or heart failure (38% vs13%; p = 0.046). In contrast, in the MINT pilot study in 
patients presenting with anaemia undergoing cardiac catheterization, patients randomized to a 
liberal blood transfusion strategy had lower rates of death, myocardial infarction, and 
unscheduled revascularization (10.9%) compared to those patients randomized to a restrictive 
transfusion strategy (25.5%), with lower 30-day mortality (1.8%) compared with restrictive 
transfusion patients (13.0%) (p = 0.032)(37). 
 Our analysis has several limitations. Although our meta-analysis suggests a dose 
dependent association between the presence of anaemia and adverse clinical outcomes in 
PCI, it cannot confer a causal relationship. Whilst the papers included in this analysis have 
adjusted for differences in clinical and procedural characteristics, renal function and 
comorbidity, we cannot rule out unmeasured confounders such as frailty or chronic disease 
that are not fully captured by statistical models that may themselves contribute to the poorer 
outcomes observed. Whilst blood sampling in the majority of the studies included in this 
meta-analysis was undertaken prior to the PCI procedure, a small number of studies included 
in this analysis, the timing of blood sampling in a small number of studies included in the 
analysis was unclear, although exclusion of these studies did not significantly alter the 
relationships reported (mortality with anaemia RR 2.39 (2.00-2.85), MACE with anaemia RR 
1.55 (1.38-1.75)). Finally, our analysis does not provide insight as to whether different 
aetiologies of anaemia have a differential relationship with clinical outcomes. 
 In conclusion, our meta-analysis of 44 studies including 230,795 patients has shown 
that the prevalence of anaemia in contemporary PCI is significant and reported at 16% and is 
independently associated with a 2-foldincreased risk of mortality, MACE events and major 
bleeding with incremental increases in risk with decreases in haemoglobin levels. This 
increased risk appears to be independent of the common causes of anaemia such as chronic 
renal disease or major bleeding events sustained peri-procedurally, and the increased risk of 
adverse events associated with anaemia is of similar magnitude irrespective of whether the 
PCI was undertaken in the elective or ACS setting. Our data support the need for a larger 
definitive trial to define the optimal treatment strategies for patients with anaemia undergoing 
PCI. 
 
Table 1: Study design and participant characteristics 
Study ID Date/Year Design  Country No. of centers Total no. of 
participants, no. 
anaemic (% 
anaemic) 
Participants 
Akgul 2013 Dec 2010 to May 
2012. 
Prospective observational 
study. 
Turkey. Single 520, 64 (12%) 
anemic. 
Participants had PPCI for STEMI. 
Ali 2004 Jul 2002 to May 
2010 
Prospective observational 
study. 
USA. Unclear. 11,991, 4,815 (40%) 
anemic. 
Participants who underwent PCI with bivalirudin. 
Ayhan 2011 Unclear. Retrospective cohort 
study. 
Turkey. Single. 2,509, 616 (25%) 
anemic. 
Participants had PPCI for STEMI. 
Bolinska 2011 May to Dec 2005. Retrospective cohort 
study. 
Poland. Single. 551, 61 (11%) 
anemic. 
Participants had PPCI for STEMI. 
Catakoglu 2007 Oct 2001 to June 
2002. 
Prospective cohort study. Turkey. Single. 100, 31 (31%) 
anemic. 
Participants had non-urgent elective PCI. 
Chi 2012 Unclear. Cohort study. China. Unclear. 1014, 253 (25%) 
anemic. 
Participants were ACS patients age ≥60 years who 
underwent PCI. 
Cho 2011a Nov 2005 to Jun 
2009. 
Retrospective cohort 
study. 
South Korea. Single. 739, 152 (21%) 
anemic. 
Participants with STEMI who underwent PPCI. 
Cho 2011b Mar 2006 to Dec 
2009 
Prospective cohort study. South Korea. Unclear. 2,849, 679 (24%) 
anemic. 
Participants were patients with drug eluting stents. 
Dada 2009 Unclear. Cohort study. USA. Unclear. 6,538, 2,159 (33%) 
anemic. 
Participants with PCI. 
Dunbar 2012 Jan 2006 to Apr 
2008. 
Retrospective cohort 
study. 
Turkey. Single center. 1,625, 395 (24%) 
anemic. 
Participants with acute STEMI and PPCI. 
Feldman 2009 2004 to 2005. Cohort study. USA. Single. 2,504, 709 (28%) 
anemic. 
Participants were in the 2004/2005 Cornell Angioplasty 
Registry who underwent urgent or elective PCI. 
Greenberg 
2010 
Jan 2001 to Dec 
2007. 
Prospective cohort study. Israel. Single. 1,042, 208 (20%) 
anemic. 
Participants had STEMI who underwent PPCI. 
Gurm 2004 Unclear. Post hoc analysis of RCT. USA. Multicenter. 6,322, 638 (10%) 
anemic. 
Participants were randomized to EPIC, EPILOG and EPI 
stent trials who underwent PCI.  
Hanna 2013 Jan 2007 to Dec 
2009. 
Cohort study. USA. 354 centers. 73,067, 2,417 (3%) 
anemic. 
Participants were in the ACTION-GWTG registry with 
NSTEMI. 
Hosseini 2014 Apr 2005 to Sept 
2008 
Cohort study. Iran. Single. 2,819, 493 (17%) 
anemic. 
Participants had elective PCI with preprocedural 
hemoglobin measured within 7 days prior to PCI. 
Husemann 
2007 
Jan 2001 to Dec 
2001. 
Retrospective cohort 
study. 
Germany. Single. 709, 128 (18%) 
anemic. 
Participants were treated with PCI. 
Jones 2010 Jan 2004 to Mar 
2009. 
Prospective cohort study. UK. Single. 1657, 331 (20%) 
anemic. 
Participants with STEMI who underwent PPCI at a 
London centre. 
Kim 2012 Jan 2004 to Dec 
2009. 
Retrospective cohort 
study. 
South Korea. Single. 3,549, 1,321 (37%) 
anemic. 
Participants received PCI with drug eluting stent in the 
CathOlic university of Korea percutAneous Coronary 
inTervention registry. 
Kitai 2013 Jan 2005 to Dec 
2007. 
Retrospective cohort 
study. 
Japan. 26 centers. 7,299, 2,209 (30%) 
anemic. 
Participants were in the CREDO-Kyoto registry cohort-2 
who underwent first elective PCI. 
Kruk 2010 Feb 2001 to Dec 
2004. 
Prospective cohort study. Poland. Unclear. 1880, 385 (20%) 
anemic. 
Participants had STEMI in a prospective registry. 
Kurek 2010 Sept 2004 to Dec 
2007. 
Prospective cohort study. Poland. Single center. 1,497, 248 (17%) 
anemic. 
Patients with AMI treated in the acute phase with PCI. 
Liu 2008 Jul 2003 to Sept 
2005. 
Cohort study. China. Single. 3,809, 744 (20%) 
anemic. 
Participants were in the DESIRE-2 revascularization 
registry. 
Liu 2009 Unclear. Cohort study. Unclear. Unclear. 3770. Participants underwent PCI. 
Maluenda 2009 2003 to 2007 Retrospective cohort 
study. 
USA. Single. 6,025, 210 (3%) 
anemic. 
Participants who underwent PCI. 
Manzano-
Fernandez 2008 
Unclear. Cohort study. Spain. 2 centers. 278, 114 (41%) 
anemic. 
Participants with AF and indication for oral 
anticoagulation who underwent PCI. 
McKechnie 
2004 
July 1997 to May 
2003. 
Prospective cohort study. USA. 18 hospitals. 48,851. Participants underwent PCI in the Blue Cross Blue Shield 
of Michigan Cardiovascular Consortium. 
Nikolsky 2004a Unclear. Post hoc analysis of RCT. International. Multicenter. 2,027, 260 (13%) 
anemic. 
Participants had AMI who underwent PPCI in 
CADILLAC trial. 
Nikolsky 
2004b 
1994 to 1999 Prospective cohort study. USA. Single. 6,929, 1,708 (25%) 
anemic. 
Participants had elective PCI. 
Oduncu 2013 Unclear. Cohort study. Turkey. Single. 2,411, 623 (26%) 
anemic. 
Participants with STEMI who underwent PPCI.  
Ozasa 2012 2005 to 2007 Retrospective cohort 
study. 
Japan. Unclear. 5,336, 1,788 (34%) 
anemic. 
Participants were in the CRED-Kyoto PCI/CABG 
Registry Cohort-2 who underwent PCI with drug eluting 
stent. 
Park 2012 2004 to 2010. Cohort study. South Korea. Unclear. 881, 349 (40%) 
anemic. 
Participants had acute MI treated with PCI. 
Poludasu 2009 Jan 2003 to Aug 
2005. 
Retrospective cohort 
study. 
USA. Unclear. 715. Participants were African-Americans from a bolus-only 
glycoprotein IIb/IIIa database. 
Rathod 2014 Jan 2004 to Aug 
2010. 
Retrospective cohort 
study. 
UK. Single. 2,178, 419 (19%) 
anemic. 
Participants had STEMI who underwent PPCI. 
Reinecke 2003 1998 to 1999 Retrospective cohort 
study. 
Germany. Single. 689. Participants were male who underwent elective PCI. 
Rodriguez 2013 2007 to 2011. Prospective cohort study. Spain. Single. 759, 226 (30%) 
anemic. 
Participants underwent PCI. 
Schroder 2013 2004 to 2006. Retrospective cohort 
study. 
Germany. Unclear. 2,056. Participants were ≥75 years who underwent PCI with 
stent implantation. 
Sgura 2010 2002 to 2008. Cohort study. Italy. Single. 673. Participants had STEMI who underwent PCI. 
Shishehbor 
2009 
Mar 2003 to June 
2007. 
Prospective cohort study. USA. Single. 2,172. Participants underwent PCI who received drug eluting or 
bare metal stent. 
Tsujita 2010 Unclear. Post hoc analysis of RCT. International. Multicenter. 3,153, 331 (10%) 
anemic. 
Participants were in HORIZONS-AMI trial who 
underwent PCI and had STEMI. 
Uchida 2013 Unclear. Cohort study. Japan. Unclear. 337, 59 (18%) Participants had STEMI who underwent PCI. 
anemic. 
Varma 2010 Apr 2003 to Dec 
2005. 
Retrospective cohort 
study. 
USA. Unclear. 120. Participants with PCI. 
Vis 2010 Jan 1997 to Mar 
2005. 
Prospective cohort study. Netherlands. Single. 292. Participants had STEMI and underwent PPCI. 
Voeltz 2007 Unclear. Post hoc analysis of RCT. International. Multicenter. 6,010, 1,371 (23%)  
anemic. 
Participants were in REPLACE-2 trial who underwent 
PCI. 
Vrslovic 2012 Unclear. Prospective cohort study. Croatia. Single. 543. Participants had STEMI who underwent PPCI. 
PPCI=primary percutaneous coronary intervention, PCI=percutaneous coronary intervention, STEMI=ST elevated myocardial infarction, RCT=randomized controlled trial. 
 
Table 2: Risk of bias table 
Study ID Ascertainment of anaemia 
and timing of assessment 
Ascertainment of outcome and 
frequency of follow up 
Lost to follow up Adjustments for confounding 
Akgul 2013 Pre-PCI anaemia from 
blood sampling. 
Hospital records or interviewing 
(directly of by telephone) patients, 
families or personal physicians. 
25 patients were 
excluded, 5 for missing 
data. 
Adjusted but for unclear variables, backward stepwise Cox regression 
analysis with variables with P<0.1. 
Ali 2004 Blood sampling with 
measured before PCI and 
6 and 12 hours after PCI. 
In-hospital complications ascertained 
daily by trained research staff. All-
cause mortality from National Social 
Security Death Index and New York 
State interventional database by 
matching patients social security 
numbers to death index records. 
27 in-patient deaths 
were excluded. 
Adjusted for age, gender, BMI, body surface area, race, indication, 
hypertension, diabetes, hyperlipidaemia, peripheral vascular disease, 
heart failure, coronary artery disease, chronic kidney disease, end stage 
renal disease, glycoprotein IIb/IIIa inhibitor use, discharge medications, 
LVEF, baseline Hb, target coronary artery, number of coronary vessels 
narrowed, stents and PCI successful. 
Ayhan 2011 Blood sampling before 
PCI. 
Hospital records or by interviewing 
(directly or by telephone) patients, their 
families, or their personal physicians. 
Lost to follow up for 46 
patients. 
Adjusted but for unclear variables.  Backward stepwise multivariate 
Cox regression analysis was used. 
Bolinska 2011 Blood sampling on 
admission. 
Retrospective review of medical 
records. 
Unclear. Adjusted for age, systolic blood pressure, Hb on admission and white 
blood count on admission. 
Catakoglu 2007 Blood sampling was 1-3 
days before procedure and 
retrieved from computer 
Endpoints were adjudicated by an 
independent clinical-events committee. 
Unclear. Adjusted for age, sex, diabetes, hypertension, smoking, LDL 
cholesterol, GFR, previous PCI and previous CABG. 
database. 
Chi 2012 Pre-procedure blood 
sampling. 
Unclear. Unclear. Adjusted but for unclear variables. 
Cho 2011a Blood sampling before 
PCI. 
Data from Korean acute MI registry.  
Follow up to 6 months. 
9 patients were lost to 
follow up. 
Crude results only for anaemia and outcomes. 
Cho 2011b Pre-procedure blood 
sampling. 
Unclear ascertainment of outcomes.  
Median follow up of 2.2 years. 
Unclear. Adjusted for baseline clinical and procedural characteristics but unclear 
variables. 
Dada 2009 Blood sampling before 
PCI. 
Unclear outcome ascertainment and 
follow up to 9 months. 
Unclear. Propensity score matched analysis likely with adjustments for age, 
diabetes, hypertension, hyperlipidaemia, renal insufficiency, prior 
history of PCI or previous CABG surgery. 
Dunbar 2012 Baseline haemogram and 
biochemical tests were 
elicited from files and 
computer records in 
hospital. Unclear timing 
of sampling. 
Unclear outcome ascertainment. Unclear. Adjusted for age, sex, diabetes, hypertension, dyslipidaemia, smoking, 
history of COPD, cardiogenic shock, history of ACEI/ARB use, 
GFR<60, history of dialysis, anterior infarct location, stent and 
tirofiban use, ST segment resolution<70%, LVEF, inotropic drug use 
and blood transfusion. 
Feldman 2009 Blood sampling with 
unclear timing of 
sampling. 
Mortality at mean follow up of 24.8 
months. Unclear method of 
ascertainment. 
Unclear. Adjusted but for unclear variables. 
Greenberg 2010 Blood sampling at 
baseline. 
Hospital charts and standardized 
questionnaire completed by telephone 
At 12 months 100% 
mortality data and 94% 
Model included age, gender, diabetes, renal insufficiency, hypertension, 
smoking, previous stroke, white blood cell, peak creatinine kinase and 
or outpatient visit up to 12 months. revascularization and 
re-infarction data. 
multivessel disease. 
Gurm 2004 Blood sampling before 
PCI. 
Mortality and MI up to 3 years. Unclear 
method of ascertainment. 
86 patients did not have 
preprocedural 
hematocrit. 
Model with interactions between variables with significant interactions 
terms incorporated into the model p value <0.05 but unclear which 
variables. 
Hanna 2013 Initial admission blood 
sampling. 
Outcomes captured in the ACTION-
GWTG database. 
579 patients were 
missing hemoglobin 
values. 
Adjusted for age, gender, race, weight, medical history of diabetes, 
previous peripheral arterial disease, hypertension, current or recent 
smoking, previous PCI, previous CABG, previous MI, previous heart 
failure, previous stroke, insurance status, home medications, systolic 
blood pressure, heart rate, heart failure or shock on admission, ECG 
findings, troponin and serum creatinine. 
Hosseini 2014 Preprocedural blood 
sampling. 
Patients were followed up by trained 
general practitioner or interventional 
cardiology fellow in clinic or through 
phone call by trained physician or 
research nurse. 
90% of patients 
completed 12 months 
follow up. 
Adjusted for age, smoking, hypertension, diabetes, creatinine clearance 
and renal failure. 
Husemann 2007 Blood sampling before 
procedure. 
Follow up with telephone calls with 
patients, relatives or referring 
physicians.  If not possible then 
questionnaire sent by mail. 
61 patients had missing 
baseline hemoglobin or 
creatinine levels. 
Follow up 100% 
complete for these 
Adjusted for covariates which were found to have a p-value <0.1 in 
univariate analyses of mortality but unclear which variables. 
patients. 
Jones 2010 Baseline blood sampling. Mortality was ascertained by 
information from the Office of National 
Statistics. 
Unclear. Adjusted for unclear variables. 
Kim 2012 Initial and follow up 
blood sampling. 
Patients were required to visit the 
outpatient clinic at 1st month and every 
3 months after PCI for outcomes up to a 
median of 25.4 months. 
129 patients were 
excluded who had 
MACE within 3 months 
for the change in 
anaemia analysis. 
Propensity matched cohort with likely inclusion of age, sex, BMI, Hb, 
GFR<60, LVEF, diabetes, hypertension, hypercholesterolemia, current 
smoking, history of MI, PCI, CABG, cerebrovascular disease, family 
history of coronary artery disease, initial diagnosis, multivessel disease 
and ACC/AHA B2/C lesions. 
Kitai 2013 Blood sampling at 
baseline. 
Follow-up data from hospital charts or 
by contacting patients or referring 
physicians. Events adjudicated by 
clinical events committee. 
96.9% patients had 1 
year follow up. 
Adjusted for age, male, BMI, hypertension, diabetes, current smoking, 
heart failure, multivessel disease, mitral regurgitation grade 3/4, LVEF, 
prior MI, prior stroke, peripheral vascular disease, eGFR, atrial 
fibrillation, platelet <100x10^9/L, COPD, liver cirrhosis, malignancy, 
number of target lesions, target proximal LAD, unprotected LMCA, 
CTO, bifurcation, total stents, stent length, minimum stent size, drug 
eluting stent, antiplatelet therapy and other medications. 
Kruk 2010 Blood sampling on 
admission prior to 
coronary procedure. 
Outcomes from hospital charts for 
death and heart failure. 
Unclear. Adjusted for sex, age, Killip class >1, prior coronary disease, smoking, 
TIMI flow, multivessel disease, systolic blood pressure, heart rate, 
white cell count, hyperglycaemia and serum creatinine. 
Kurek 2010 Blood sampling just after 
admission before transfer 
MACE and death from computerized 
database and long-term outcomes from 
Unclear. Adjusted for diabetes, incomplete revascularization, multivessel 
disease, impaired renal function, advance age and left ventricular 
to catheter laboratory. a database of the National Fund of 
Health. 
dysfunction. 
Liu 2008 Pre-PCI blood sampling. Unclear. Unclear. Adjusted for comorbidities but unclear variables. 
Liu 2009 Pre-PCI blood sample. Unclear. Unclear. Unclear. 
Maluenda 2009 Blood sampling before 
and after PCI. 
Independent research personnel 
conducted follow up via telephone or 
office visits.  All clinical events 
adjudicated by independent physicians. 
Unclear. Unadjusted for haematocrit analysis.  
Manzano-
Fernandez 2008 
Blood sampling at 
baseline. 
Unclear. Unclear. Adjusted but for unclear variables. 
McKechnie 2004 Preprocedural blood 
sampling. 
Outcome data collected prospective 
from standardized form. 
Missing or implausible 
hemoglobin for 3,686 
cases. 
Adjusted for unclear variables.  Variables with p<0.2 in univariate 
analysis were included in stepwise regression for each outcome. 
Nikolsky 2004a Blood sampling at initial 
presentation. 
Clinical follow up at 30 days, 6 months, 
1 year and all events were adjudicated 
by independent clinical events 
committee. 
Unclear. Adjusted but for unclear variables. 
Nikolsky 2004b Blood samplings before 
PCI and after PCI. 
Telephone interviews for out of hospital 
outcomes at 12 months. 
1 year follow up 
available for 89% of 
patient with anaemia 
versus 90.2% who did 
Adjusted for age, gender, BMI, angina class III or IV, diabetes mellitus, 
history of peripheral arterial disease, angiographic characteristics, 
creatinine clearance and anaemia. 
not have anaemia. 
Oduncu 2013 Blood sampling on 
admission. 
Unclear method of ascertainment 
follow up up to 48 months. 
Unclear. Adjusted but for unclear variables. 
Ozasa 2012 Unclear timing of blood 
sampling. 
Unclear. Unclear. Adjusted for unclear variables. 
Park 2012 Blood sampling at 
baseline. 
Unclear followed up for up to 2 years. Unclear. Adjusted for unclear variables. 
Poludasu 2009 Blood sampling at 
baseline. 
Social Security Death Index for death. 131 patients did not 
have valid Social 
Security number. 
Adjusted for unclear variables. 
Rathod 2014 Blood sampling at 
baseline. 
In-hospital events were recorded 
prospectively.  Long term data from 
British Cardiovascular Intervention 
Society database. 
240 patients excluded 
because of incomplete 
data sets. 
Propensity score matched for age, sex, diabetes, hypertension, 
hypercholesterolaemia, previous CABG, previous PCI, previous MI, 
multivessel disease, eGFR, ejection fraction, glycoprotein IIb/IIIa 
inhibitor. 
Reinecke 2003 Blood sampling 1 to 3 
days before the procedure. 
Follow up with questionnaire sent to all 
patients or telephone call with patients, 
relatives or referring physicians. 
11 patients had no 
baseline hemoglobin 
and were excluded. 
Adjusted for number of diseased vessels, smoking, creatinine, stent 
implantation, age, family history of cardiovascular disease, diabetes. 
Rodriguez 2013 Blood sampling on 
admission. 
Unclear outcome ascertainment with 
mean follow up of 26.5 months. 
None. Adjusted for unclear variables. 
Schroder 2013 Blood sampling at time of 
hospital admission. 
Follow-up questionnaire or telephone 
interview with patient or relative, 
contact patient's physician or registry 
office. 
Unclear. Adjusted for age, gender, Hb, serum CRP, serum LDL, and serum 
creatinine levels, and LVEF). 
Sgura 2010 Blood sampling on 
admission. 
Unclear but follow up was 30 months. Unclear. Crude results. 
Shishehbor 2009 Blood sample pre-PCI. Mortality from Social Security Death 
Index at a median of 1.8 year follow up. 
Unclear. Adjusted for age, gender, socioeconomic class, BMI, heart rate, LVEF, 
malignancy, depression, diabetes, family history, current smoking, 
blood markers, medical history, NYHA functional class, medications, 
type of anaemia, angiographic data, lesion location, procedural data. 
Tsujita 2010 Blood sampling at initial 
presentation. 
All events were adjudicated by an 
independent clinical events committee 
blinded to treatment assignment. 
Unclear. Adjusted for age, gender, race, hypertension, hyperlipidaemia, 
smoking, diabetes mellitus, peripheral vascular disease, congestive 
heart failure, angina, PCI, MI, CABG, Killip class, BMI, anaemia, 
platelet count, white blood count, creatinine clearance <60 ml/min, 
LAD coronary artery infarct vessel, reference vessel diameter, target 
lesion length, LVEF, index hospitalization, duration from symptom 
onset to first balloon inflation, antithrombotic randomization, 
clopidogrel loading dose, randomization to paclitaxel-eluting stent vs 
bare-metal stent, number of stents, use of heparin before randomization 
and final TIMI flow grade 3. 
Uchida 2013 Baseline blood sampling. Unclear outcome ascertainment and 
follow up. 
Unclear. Adjusted but for unclear variables. 
Varma 2010 Blood was sampled 72 
hours preintervention. 
Mortality from Social Security database 
and hospital computer database with 
follow up of median 30 months. 
Unclear. Unadjusted. 
Vis 2010 Admission blood sample. Data from questionnaire, review of 
outpatient reports, general practitioners 
were contacted by phone or municipal 
death registry were consulted. 
165 patients had 
missing data. 
Adjusted for glucose, Hb and CrCl on admission, LVEF<40%, age, sex, 
TIMI flow less than 3, the presence of multivessel disease, ischemic 
and door-to-balloon times and the presence of diabetes on admission. 
Voeltz 2007 Blood sampling at 
baseline. 
End points determined by blinded 
clinical events committee. 
Unclear. Adjusted for unclear variables. 
Vrsalovic 2012 Blood sampling on 
admission. 
30 day outcomes based on medical 
documentation, telephone interviews 
with the patient, their family members 
or home physicians. 
Unclear. Adjust for PAMI risk score, gender, peak creatinine kinase value, 
admission troponin T, baseline serum creatinine, platelet count, time to 
treatment, initial and final TIMI flows, LVEF, in hospital medications, 
multivessel disease, CRP and mean platelet volume. 
PCI= percutaneous coronary intervention, BMI=body mass index, Hb=haemoglobin, LDL=low density lipids, GFR=glomerular filtration rate, CABG=coronary artery bypass graft, 
MI=myocardial infarction, LVEF=left ventricular ejection fraction. 
Table 3: Study results 
Study ID Definition of 
anaemia/hemoglobin/ 
hematocrit groups 
Outcomes and 
timepoint of follow up 
No. of events in anemic group No. of events in non-anemic 
group 
Results 
Akgul 2013 Anaemia defined by Hb 
<13 mg/dl in men and <12 
mg/dl in women. 
6 month cardiovascular 
mortality. 
Unclear. 64 anemic patients. Unclear. 456 non-anemic 
patients. 
6 month cardiovascular mortality: 
Multivariate OR: 3.9 (1.52-10.2). 
Ali 2004 Anaemia defined as Hb 
<13 g/dl in men, <12 g/dl 
in women.  Bloods before 
PCI, 6 and 12 hours post 
PCI. 
Median follow up of 
2.6 years for mortality. 
Major bleed 159/4,815. Major bleed 51/7,176. Long term (median 2.6 years) 
mortality with anaemia: multivariate 
OR: 1.8 (1.6-2.0).  In-hospital major 
bleeding and anaemia: multivariate 
OR: 3.3 (2.3-4.6). 
Ayhan 2011 Anaemia defined by Hb 
<13 g/dl for men and <12 
g/dl for women. 
In-hospital: mortality, 
re-infarction, MACE 
(cardiac death, re-
infarction, target vessel 
revascularization), 
major bleeding 
requiring transfusion. 
Long term 
cardiovascular 
Crude events in-hospital:  
mortality 31/616, re-infarction 
14/616, MACE 61/616, major 
bleeding requiring transfusion 
65/616. Long term cardiac 
events: 56/574, re-infarction 
47/574, MACE 157/574. 
Crude events in-hospital:  
mortality 35/1893, re-
infarction 36/1893, MACE 
104/1893, major bleeding 
requiring transfusion 27/1893. 
Long term cardiac events: 
72/1823, re-infarction 
175/1823, MACE 430/1823. 
Long term cardiovascular mortality 
with anaemia: multivariate OR 2.2 
(1.2-4.0). 
mortality, re-infarction 
and MACE. 
Bolinska 2011 Anaemia defined by Hb, 
<12 g/dl for women and 
<13 g/dl for men. 
In-hospital death and 
cardiovascular events. 
In-hospital death: 5/61. CV 
complications 20/61 (33%). 
In-hospital death: 3/490. CV 
complications: 83/490 (17%). 
Risk factor for death or 
cardiovascular complication: 
multivariate Hb on admission OR 
0.89 (0.754-1.051). 
Catakoglu 2007 Anaemia defined by 
hematocrit <39% for men 
and <36% for women.  
Nonfatal coronary 
events (MI, CABG or 
repeat PCI) during 1 
year follow up. 
Non-fatal coronary events: 
23/31. 
Non-fatal coronary events: 
26/69. 
Nonfatal coronary events with 
anaemia: multivariate OR 2.507 
(1.379-4.555). 
Chi 2012 Anaemia defined by Hb 
<130 g/l in men, <120 g/l 
in women. 
Long term mortality at 
follow up of 528 days. 
Unclear. Unclear. Long term mortality with anaemia: 
RR 3.293 (1.431-7.578). 
Cho 2011a Anaemia defined by Hb 
<13 mg/dl in men and <12 
mg/dl in women. 
Death or MACE at 1 
month and 6 months. 
1 month: MACE 22/182, 
death 16/182. 6 months: 
MACE 43/182, death 23/182. 
1 month: MACE  29/557, 
death 17/557. 6 months: 
MACE 76/557, death 22/557. 
See crude results. 
Cho 2011b Anaemia defined by Hb 
<12 g/dl for women, <13 
g/dl for men. 
Mortality and MACE at 
2 years. 
Mortality: 34/679. MACE 
44/679. 
Mortality: 39/2170. MACE: 
52/2170. 
Anaemia and risk of mortality: 
multivariate HR 1.52 (0.90-2.56). 
Anaemia and risk of MACE: 
multivariate HR 1.78 (1.14-2.78). 
Dada 2009 Anaemia defined by Hb In-hospital and 9 month Unclear. Unclear. Anaemia and in-hospital mortality: 
<13 g/dl for men and <12 
g/dl for women. 
mortality. propensity matched OR 2.87 (1.58-
6.23). Anaemia and 9 month 
mortality: propensity matched OR 
1.46 (1.07-1.99).  
Dunbar 2012 Not WHO criteria. In-hospital events: 
mortality, re-infarction, 
congestive heart failure, 
TIMI major bleeding. 
Unclear. Unclear. Adjusted risk of in-hospital mortality 
per 1 g/dl decrease: OR 1.28 (1.01-
1.63).  
Feldman 2009 Anaemia defined by Hb 
≤12 g/dl. Post-PCI bleed 
defined yb drop in Hb ≥2 
g/dl. 
In-hospital: death MI, 
MACE. 1 year death. 
Death followed up for 
mean of 24.8 months. 
Anemic and bleed total 53. In-
hospital death 3/53 (5.7%), 
MI 7/53 (13.2%), MACE 9/53 
(17.0%). 1 year death 8/53 
(15.1%). Long term death 
13/53 (24.5%). Anemic and 
no bleed total 656. In-hospital 
death 2/656 (0.3%), MI 
40/656 (6.1%), MACE 42/656 
(6.4%). 1 year death 30/656 
(4.6%). Long term death 
53/656 (8.1%). 
Not anemic and bleed total 
290. In-hospital death 0/290 
(0%), MI 38/290 (12.4%), 
MACE 38/290 (13.1%). 1 
year death 13/290 (4.5%). 
Long term death: 16/290 
(5.5%).  Not anemic and no 
bleed total 1505. In-hospital 
death 2/1505 (0.1%), MI 
99/1505 (6.6%), MACE 
101/1505 (6.7%). 1 year death 
26/1505 (1.7%). Long term 
death: 47/1505 (3.1%). 
See crude results. 
Greenberg 2010 3 groups: Anemic <36% 
women, <39% men, 
Normal 36-46 women, 39-
47% men, Erythrocytosis 
>46% women, >47% men. 
Mortality, re-infarction, 
MACE up to 12 
months. 
1 month: mortality 15/208, re-
infarction 16/208. 6 month 
mortality 19/208, re-infarction 
23/208. 12 month mortality 
15/208, re-infarction 27/208, 
MACE: 65/208. 
1 month: mortality 22/834, re-
infarction 19/834. 6 month 
mortality 37/834, re-
infarction 34/834. 12 month 
mortality 52/834, re-
infarction 49/834, MACE: 
181/834. 
Anaemia and 1 month mortality: OR 
3.5 (1.6-7.5). 
Gurm 2004 Continuous hematocrit. 30 day and 6 month 
MI/mortality. 3 year 
mortality. 
Unclear. Unclear. Continuous hematocrit and 3 year 
mortality: multivariate HR 0.953 
(0.930-0.977). 
Hanna 2013 Not WHO criteria. In-hospital death. Unclear. Unclear. Death per 1 g/dl decrease in 
hemoglobin <15 g/dl: multivariate 
OR 1.07 (1.02-1.11) 
Hosseini 2014 Anaemia defined by Hb 
>12 g/dl for women, >13 
g/dl for men. 
In-hospital MACE, MI, 
death. 
In-hospital: 2/493 MACE, 
1/493 MI, 0/493 death. 12 
month: 24/493 MACE, 
11/493 MI, 4/493 death. 
In-hospital: 11/2326 MACE, 
8/2326 MI, 2/2326 death. 12 
month: 71/2326 MACE, 
20/2326 MI, 13/2326 death. 
Adjusted risk of 12 month MACE: 
mild anaemia HR 1.249 (0.652-
2.390), moderate anaemia HR 1.462 
(0.584-3.660), severe anaemia HR 
4.623 (1.642-13.021). 
Husemann 2007 Continuous Hb. In-hospital and long 
term mortality and MI. 
 
Unclear. Unclear. Multivariate hazard ratio for mortality 
per unit increase in hemoglobin 
concentration: HR 0.711 (0.616-
0.819). 
Jones 2010 Anaemia defined by <12 
g/dl for women and <13 
g/dl for men. 
Mortality at 3 years. Mortality at 3 years: 64/331. Mortality at 3 years: 
166/1326. 
Anaemia and mortality at 3 years: 
multivariate OR 2.4 (1.1-3.7). 
Kim 2012 Anaemia defined by Hb 
<12 g/dl in women and <13 
g/dl in men. Also grouped 
as sustained or improved 
anaemia at 3 months. 
MACE, MI, death at 
median follow up of 
25.4 months. 
Unclear. Unclear. Anaemia and MACE (death, MI, 
stroke): multivariate HR 1.479 
(1.025-2.134). Anaemia and death: 
multivariate HR 1.943 (1.241-3.043). 
Anaemia and MI: multivariate HR 
1.182 (0.476-2.936).  
Kitai 2013 Anaemia defined by Hb 
<12.0 g/dl for women, 
<13.0 g/dl for men. 
3 years MACE, death, 
MI. 
3 years: MACE 466/2206, 
death 274/2206, MI 77/2206. 
3 years: MACE 348/5093, 
death 150/5093, MI 
112/5093. 
Mild anaemia and moderate to severe 
anaemia: MACE HR 1.77 (1.47-
2.15), HR 2.53 (2.03-3.14), death HR 
1.86 (1.42-2.42), HR 3.35 (2.52-
4.47), MI HR 1.14 (0.74-1.75), HR 
1.87 (1.13-3.09). 
Kruk 2010 Anaemia defined by 
hematocrit <39% for men 
and <36% for women. 
In-hospital death and 
heart failure. 
Unclear. Unclear. Anaemia and death: HR 2.03 (1.19-
3.46). Anaemia and heart failure: HR 
1.09 (0.79-1.51). Anaemia and death 
and heart failure: HR 1.34 (0.98-
1.82). Anaemia and bleeding: HR 
1.67 (1.12-2.45). 
Kurek 2010 Anaemia defined by Hb 
<13 g/dl for men and <12 
g/dl for women. 
MACE and death mean 
follow up of 18.5 
months. 
Unclear. Unclear. Anaemia and in-hospital death: 
multivariate HR 1.30 (1.09-1.21). 
Anaemia and 30 day death: 
multivariate HR 1.19 (0.98-1.40). 
Anaemia and 1 year death: 1.31 
(1.14-1.48). Anaemia and long term 
mortality: multivariate HR 1.45 (1.29-
1.61). MACE 30 days: multivariate 
HR 1.35 (1.17-1.53). MACE 1 year: 
multivariate HR 1.14 (1.03-1.25). 
Liu 2008 Anaemia defined by <120 
g/l in women, <130 g/l in 
men. 
Mortality and MACE 
(nonfatal MI, stroke and 
revascularization). 
Mortality: 35/744 (4.7%). 
MACE: 104/744 (14.0%). 
Mortality: 46/3065 (1.5%). 
MACE: 331/3065 (10.8%). 
Anaemia and mortality: multivariate 
RR 2.216 (1.019-4.428) 
Liu 2009 Continuous Hb. Mortality with unclear 
follow up. 
Unclear. Unclear. Hemoglobin and long term mortality: 
HR 0.952 (0.921-0.984). 
Maluenda 2009 Continuous hematocrit. 1 year mortality or 
nonfatal MI. 
Unclear. Unclear. Unadjusted baseline hematocrit and 1 
year outcome: death HR 0.92 (0.91-
0.93), MI HR 0.94 (0.91-0.97), death 
or MI HR 0.92 (0.91-0.93).  
Manzano- Anaemia defined by Hb Major bleeding with Major bleed: 23/114 (20%). Major bleed: 18/164 (10.7%). Anaemia and major bleed: 
Fernandez 2008 <12.0 g/dl for women and 
<13/0 g/dl for men. 
median follow up 19.2 
months. 
multivariate HR 2.15 (1.08-4.30). 
McKechnie 
2004 
Anaemia defined by Hb 
<12.0 g/dl in women and 
<13.0 g/dl in men. 
In-hospital MACE, 
mortality and MI. 
Unclear. Unclear. Multivariate anaemia and in-hospital 
mortality: OR 2.29 (1.79-2.92). 
Multivariate anaemia and in-hospital 
MACE: OR 1.2 (1.05-1.34). 
Decreasing hemoglobin and in-
hospital mortality: men adjusted OR 
1.21 (1.14-1.28), women adjusted OR 
1.05 (0.97-1.14). 
Nikolsky 2004a Anaemia defined by  
hematocrit <39% for men 
and <36% for women. 
Follow up 30 days, 6 
months and 1 year. 
Mortality: in-hospital 12/260 
(4.6%), 30 day 15/260 (5.8%), 
1 year 27/260 (10.2%). 
Cardiac mortality: in-hospital 
6/260 (2.4%), 30 day 
mortality 7/260 (2.8%), 1 year 
mortality 16/260 (6.1%). Re-
infarction: in-hospital 2/260 
(0.8%), 30 day 4/260 (1.6%), 
1 year 8/260 (2.9%). MACE: 
in-hospital 20/260 (7.7%), 30 
Mortality: in-hospital 
19/1,767 (1.1%), 30 day 
27/1,767 (1.5%), 1 year 
62/1,767 (3.5%). Cardiac 
mortality: in-hospital 
18/1,767 (1.0%), 30 day 
25/1,767 (1.4%), 1 year 
44/1,767 (2.5%). Re-
infarction: in-hospital 4/1,767 
(0.2%), 30 day 12/1,767 
(0.7%), 1 year 41/1,767 
Baseline anaemia and in-hospital 
mortality: multivariate HR 3.26 (1.01-
10.52). Baseline anaemia and 1 year 
mortality: multivariate HR 2.38 (1.18-
4.81). 
day 27/260 (10.4%), 1 year 
53/260 (20.3%). 
(2.3%). MACE: in-hospital 
64/1,767 (3.6%), 30 day 
92/1,767 (5.2%), 1 year 
306/1,767 (17.3%). 
Nikolsky 2004b Anaemia defined by 
hematocrit <39% for men 
and <36% for women.  
In-hospital and 1 year 
mortality and MI. 
In-hospital mortality 32/1,708 
(1.9%), cardiac mortality 
20/1,708 (1.2%), 1 year MI 
132/1,708 (7.7%). 
In-hospital mortality 21/5,221 
(0.4%), cardiac mortality 
16/5,221 (0.3%), 1 year MI 
271/5,221 (5.2%). 
Anaemia and 1 year mortality: 
multivariate OR 1.88 (1.46-2.43). 
Oduncu 2013 Anaemia defined by Hb 
<13 mg/dl in men and <12 
mg/dl in women. 
Mortality, major 
bleeding and MACE up 
to 48 months. 
In-hospital mortality 49/623 
(7.9%), major bleeding 
43/623 (6.9%). Long term 
mortality 165/623 (26.5%), 
heart failure 55/623 (8.9%), 
re-infarction 67/623 (10.8%). 
In-hospital mortality 41/1,788 
(2.3%), major bleeding 
45/1,788 (2.5%). Long term 
mortality 191/1,788 (10.7%), 
heart failure 88/1,788 (4.9%), 
re-infarction 141/1,788 
(7.9%). 
Anaemia and MACE: multivariate 
HR 3.12 (1.15-6.59). 
Ozasa 2012 Anaemia defined by Hb 
<13 g/dl for men and <12 
g/dl for women. 
All-cause and cardiac 
death unclear follow up. 
All-cause mortality 293/1,788 
(16.4%), cardiac mortality 
127/1,788 (7.1%). 
All-cause mortality 128/3,548 
(3.6%), cardiac mortality 
60/3,548 (1.7%). 
Anaemia and all-cause mortality: 
multivariate HR 1.96 (1.49-2.58). 
Anaemia and cardiac mortality: 
multivariate HR 1.36 (0.90-2.06). 
Park 2012 Anaemia defined by Hb 
<13 g/dl for men and <12 
Mortality, cardiac 
death, MI and MACE 
Mortality 46/349, cardiac 
death 36/349, MI 14/349, 
Mortality 21/532, cardiac 
death 17/532, MI 10/532, 
Anaemia and 2 year mortality: OR 
3.78 (2.19-6.52). 
g/dl for women. up to 2 years. MACE 78/349. MACE 78/532. 
Poludasu 2009 Anaemia defined by Hb 
<13 g/dl for men and <12 
g/dl for women. Also 
grouped by Hb <11.1 and 
≥11.1 to <12.6. 
In-hospital MACE, 
death, MI and bleeding 
and mortality at 3.2 
years. 
In-hospital: MACE 22/313, 
death 0/313, MI 13/313, 
bleeding 9/313. Long term 
mortality 50/313. 
In-hospital: MACE 27/402, 
death 0/402, MI 19/402, 
bleeding 8/402. Long term 
mortality 24/402. 
Use crude results. 
Rathod 2014 Anaemia defined by Hb 
<12 g/dl for women, <13 
g/dl for men. 
MACE, MI and death at 
3 years. 
In-hospital: major bleeding 
19/419, mortality 35/419. 3 
year: MACE 101/419, MI 
23/419, death 75/419. 
In-hospital: major bleeding 
30/1,759, mortality 51/1,759. 
3 year: MACE 228/1,759, MI 
61/1,759, death 106/1,759. 
Anaemia and mortality with 
propensity score match: HR 1.14 
(0.52-2.49). 
Reinecke 2003 Anaemia defined by Hb 
<13.0 g/dl (only male 
participants studied) 
In-hospital mortality, at 
median 697 day follow 
up death, cardiac death, 
nonfatal MI. 
In-hospital death: 1/144. 
Follow up death 30/144, 
cardiac death 19/144, nonfatal 
MI 4/144. 
In-hospital death: 2/545. 
Follow up death 32/545, 
cardiac death 25/545, nonfatal 
MI 22/545. 
Unadjusted hemoglobin and death at 
follow up: HR 0.68 (0.59-0.78). 
Anaemia and mortality: HR 4.09 
(1.52-11.05). 
Rodriguez 2013 Anaemia defined by <13 
g/dl for men and <12 g/dl 
for women. 
Bleeding, cardiac 
mortality, all-cause 
mortality at follow up 
of 26.5 months. 
Bleeding 44/226 (19.5%), 
mortality 120/226 (5.3%). At 
follow up cardiac mortality 
18/226 (8%), all-cause 
mortality 46/226 (20.4%). 
Bleeding 46/533 (8.6%), 
mortality 8/533 (1.5%). At 
follow up cardiac mortality 
15/533 (2.8%), all cause 
morality 26/533 (4.9%). 
Anaemia and mortality: multivariate 
HR 2.1 (1.1-4.1) 
Schroder 2013 Continuous Hb. Mortality at mean 
follow up of 137 weeks. 
Unclear. Unclear. Hemoglobin and mortality: 
multivariate HR 0.784 (0.62-0.991). 
Sgura 2010 Anaemia defined by Hb 
<12 g/dl for women and 
<13 g/dl for men. 
Mortality and MACE at 
mean of 30 months. 
Mortality 26/128 (20.3%), 
MACCE 40/128 (31.2%). 
Mortality 57/545 (10.5%), 
MACCE 118/545 (21.6%). 
See crude results. 
Shishehbor 2009 Continuous hematocrit. Mortality and study 
took place over 4.5 year 
interval. 
Unclear. Unclear. Continuous hematocrit and mortality: 
multivariate HR 0.93 (0.91-0.96).  
Tsujita 2010 Anaemia defined by 
hematocrit <39% for men 
and <36% for women. 
Anaemia at presentation.  
Death, cardiac death, 
re-infarction, TIMI 
major bleed, MACE up 
to 1 year. 
30 day: death 16/331(4.8%), 
cardiac death 28/331 (8.5%), 
re-infarction 6/331 (1.9%), 
TIMI major bleeding 13/331 
(4%), MACE 27/331 (8.2%). 
1 year: death 28/331 (8.5%), 
cardiac mortality 19/331 
(5.8%), re-infarction 15/331 
(4.5%), TIMI major bleeding 
15/331 (4.6%), MACE 61/331 
(18.4%).  
30 day: death 62/2,822 
(2.2%), cardiac death 
56/2,822 (2.0%), re-infarction 
56/2,822 (2.0%), TIMI major 
bleeding 99/2,822 (3.5%), 
MACE  141/2,822 (5.0%). 1 
year: death 102/2,822 (3.6%), 
cardiac death 73/2,822 
(2.6%), re-infarction 
119/2,822 (4.2%), TIMI 
major bleeding 104/2,822 
(3.7%), MACE 325/2,822 
(11.5%). 
Multivariate anaemia and mortality at 
1 year: HR 1.98 (1.05-3.73). 
Multivariate anaemia and major 
bleeding: HR 2.15 (1.43-3.24). 
Uchida 2013 Anaemia defined by Hb 
<13 g/dl for men and <12 
Cardiac death or 
hospitalization for 
Unclear. Unclear. Anaemia and adverse events: 
multivariate HR 2.58 (1.01-6.60). 
g/dl for women. congestive heart failure. 
Varma 2010 Anaemia defined by Hb 
<13.0 g/dl for men and Hb 
<12.0 g/dl for women. 
Mortality at median of 
30 months. 
Death 8/30 (25%), cardiac 
death 2/30 (8%). 
Death 5/90 (6%), cardiac 
death 1/90 (1%). 
See crude results. 
Vis 2010 Continuous Hb. 1 year mortality. Unclear. Unclear. 1 year mortality by hemoglobin: 
multivariate OR 0.992 (0.992-1.423).  
Voeltz 2007 Anaemia defined by Hb 
<12.0 g/dl for women and 
<13.0 g/dl for men. 
Major bleeding, MACE 
(death MI, 
revascularization), 
mortality and MI. 
TIMI major bleeding 15/1,371 
(1.1%), MACE 30 days 
104/1371 (7.6%), MI 30 days 
95/1371 (6.9%), death 30 
days 12/1371 (0.9%). death 6 
months 36/1371 (2.6%), death 
1 year 59/1371 (4.3%). 
TIMI major bleeding 
30/4,499 (0.7%), MACE 30 
days 328/4498 (7.3%), MI 30 
days 292/4498 (6.5%), death 
30 days 9/4498 (0.2%), death 
6 months 31/4498 (0.7%), 
death 1 year  67/4498 (1.5%). 
Multivariate anaemia and 1 year 
mortality adjusted for transfusions: 
HR 1.84 (1.22-2.78). 
Vrsalovic 2012 Anaemia defined by Hb 
<13 g/dl for men and <12 
g/dl for women. 
Mortality at 30 days. Unclear. Unclear. Multivariate 30 day mortality with 
anaemia: OR 2.69 (1.24-5.86). 
Figure 1: Flow diagram of study selection 
760 results from search of MEDLINE 
and EMBASE shown in 
Supplementary Data 1. 
74 studies were downloaded and 
reviewed in data for potential 
inclusion. 
686 results were excluded because 
they clearly did not meet inclusion 
criteria. 
30 results were excluded for the 
following reasons: no results (n=12), 
duplicates (n=4), blood tests post 
PCI (n=6), not WHO anaemia criteria 
(n=6) and not PCI (n=2). 44 studies were included in the 
meta-analysis. 
Figure 2:Risk of mortality with anaemia compared to no anaemia 
 
Figure 3:Risk of major adverse cardiovascular events with anaemia compared to no anaemia 
 
Figure 4:Risk of re-infarction with anaemia compared to no anaemia 
 
Figure 5:Risk of bleeding with anaemia compared to no anaemia 
 
Figure 6:Risk of adverse outcomes by incremental decrease in haemoglobin (Hb) or 
haematocrit (Hct) 
 
Figure 7: Subgroup analysis of risk of mortality with anaemia compared to no anaemia 
 
Supplementary Data 1:Search strategy 
No. Search terms Results 
1 PCI.mp. [mp=ti, ab, sh, hw, tn, ot, dm, mf, dv, kw, nm, kf, px, rx, ui] 41063 
2 coronary-intervention.mp. [mp=ti, ab, sh, hw, tn, ot, dm, mf, dv, kw, nm, kf, 
px, rx, ui] 
59810 
3 coronary-angioplasty.mp. [mp=ti, ab, sh, hw, tn, ot, dm, mf, dv, kw, nm, kf, 
px, rx, ui] 
42063 
4 1 or 2 or 3 110471 
5 anaemia.mp. [mp=ti, ab, sh, hw, tn, ot, dm, mf, dv, kw, nm, kf, px, rx, an, ui] 57957 
6 anaemia.mp. [mp=ti, ab, sh, hw, tn, ot, dm, mf, dv, kw, nm, kf, px, rx, an, ui] 377829 
7 5 or 6 394945 
8 4 and 7 896 
9 Deduplication 760 
Supplementary Table 2: Sensitivity analysis by indication 
Sensitivity analysis for mortality by indication No. of 
studies 
Risk ratio [95% 
CI] 
Unadjusted mortality in ACS only 4 3.12 [1.89, 5.16] 
Unadjusted mortality in any PCI 4 3.76 [2.35, 6.00] 
Adjusted mortality in ACS only 12 2.33 [1.69, 3.21] 
Adjusted mortality in elective only 4 2.00 [1.64, 2.43] 
Adjusted mortality in any PCI 8 1.90 [1.74, 2.08] 
Incremental decrease in Hb and mortality in ACS only 3 1.08 [1.00, 1.17] 
Incremental decrease in Hb mortality in elective only 1 1.47 [1.28, 1.69] 
Incremental decrease Hb in any PCI 3 1.22 [0.98, 1.52] 
Continuous hematocrit mortality in any PCI 3 1.07 [1.05, 1.10] 
    
Sensitivity analysis for MACE by indication No. of 
studies 
Risk ratio [95% 
CI] 
Unadjusted MACE in ACS only 9 1.64 [1.41, 1.91] 
Unadjusted MACE in elective only 1 1.04 [0.84, 1.29] 
Unadjusted MACE in any PCI 3 1.12 [0.89, 1.41] 
Adjusted MACE in ACS only 3 1.93 [1.06, 3.50] 
Adjusted MACE in elective only 1 2.11 [1.49, 2.99] 
Adjusted MACE in any PCI 3 1.63 [1.25, 2.12] 
Incremental decrease in Hb MACE in any PCI 1 1.09 [1.08, 1.10] 
  
Sensitivity analysis for reinfarction by indication No. of 
studies 
Risk ratio [95% 
CI] 
Unadjusted reinfarction in ACS only 6 1.57 [1.13, 2.18] 
Unadjusted reinfarction in elective only 1 1.07 [0.86, 1.34] 
Unadjusted reinfarction in any PCI 3 0.87 [0.65, 1.16] 
Adjusted reinfarction in elective only 2 1.84 [1.07, 3.18] 
Adjusted reinfarction in any PCI 1 1.18 [0.48, 2.94] 
Incremental decrease in Hb reinfarction in any PCI 1 1.06 [1.03, 1.10] 
 Sensitivity analysis for bleeding by indication No. of 
studies 
Risk ratio [95% 
CI] 
Unadjusted bleeding in ACS only 4 2.82 [1.34, 5.96] 
Unadjusted bleeding in elective only 1 1.64 [0.89, 3.03] 
Unadjusted bleeding in any PCI 3 1.12 [0.32, 3.88] 
Adjusted bleeding in ACS only 1 1.67 [1.13, 2.47] 
Adjusted bleeding in any PCI 2 2.97 [2.07, 4.26] 
 
Supplementary Figure 1: Effect of anaemia and low haemoglobin on 30-day mortality by 
indication 
 
Supplementary Figure 2: Effect of anaemia and low haemoglobin on in-hospital MACE by 
indication 
 
Supplementary Figure 3: Effect of anaemia and low haemoglobin on in-hospital 
reinfarction by indication 
 
 
Supplementary Figure 4: Effect of anaemia and low haemoglobin on in-hospital bleeding 
by indication 
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